These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 27058207)

  • 21. Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma.
    Sales AHA; Bette S; Barz M; Huber T; Wiestler B; Ryang YM; Schmidt-Graf F; Liesche F; Combs SE; Meyer B; Gempt J
    J Neurooncol; 2019 May; 142(3):529-536. PubMed ID: 30790133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.
    Papacocea SI; Vrinceanu D; Dumitru M; Manole F; Serboiu C; Papacocea MT
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
    Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
    Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glioblastoma survival is better analyzed on preradiotherapy MRI than on postoperative MRI residual volumes: A retrospective observational study.
    De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Charni S; Cohen-Jonathan-Moyal E; Roux FE
    Clin Neurol Neurosurg; 2020 Sep; 196():105972. PubMed ID: 32512407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
    Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
    J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
    Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
    World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
    Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
    J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
    Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
    Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
    Li YM; Suki D; Hess K; Sawaya R
    J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.
    Rammohan N; Ho A; Saxena M; Bajaj A; Kruser TJ; Horbinski C; Korutz A; Tate M; Sachdev S
    J Neurooncol; 2022 Jul; 158(3):331-339. PubMed ID: 35525907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
    Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
    J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Volumetric Analysis Using Low-Field Intraoperative Magnetic Resonance Imaging for 168 Newly Diagnosed Supratentorial Glioblastomas: Effects of Extent of Resection and Residual Tumor Volume on Survival and Recurrence.
    Fukui A; Muragaki Y; Saito T; Maruyama T; Nitta M; Ikuta S; Kawamata T
    World Neurosurg; 2017 Feb; 98():73-80. PubMed ID: 27989974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.